Study of the clinical use of positron emission tomography in the practice of oncological gynecology at the women’s hospital
Abstract
PET (Positron Emission Tomography) with 18-fluorine-deoxy-glucose (18FDG) as a radiopharmaceutical is a diagnostic technique for non-invasive nuclear medicine whose indications are mainly linked to oncological pathologies.
Objective: to assess the indication and impact of PET with 18FDG in the care of women with gynecological oncological pathology.
Study: retrospective descriptive by reviewing medical records of patients with gynecological cancer assisted at the Women's Hospital (HM), who underwent a PET with 18FDG in the diagnostic evaluation or in the follow-up in the period between 1/1/2014 and 12/31/2017. A total of 68 patients were analyzed in which 112 PET were performed with 18FDG. Regarding the indication, in cases of neck cancer (CC), the majority (51.5%) of PET
they were performed on suspicion of recurrence; in breast cancer (CM) in the evolutionary control, (44.6%); in cancers of
endometrium (EC) on suspicion of recurrence (50%); in ovarian cancers 37.5% on suspicion of recurrence and equal
percentage in evolutionary control; in vulvar (CV) cancers in post-treatment control or suspected recurrence (50% each).
Regarding the impact on clinical behavior, overall, in CC cases, 60% of the studies carried out determined
changes in clinical behavior; in the CM, 49%; in the EC, 43%; in CO, 50%; in CVs, 50%. PET with 18FDG
It is a technique that has been incorporated into gynecological clinical practice and still requires incorporating the guidelines of its
utilization.
References
(1) Comisión Honoraria de Lucha Contra el Cáncer. Registro Nacional de Cáncer. Situación epidemiológica del Uruguay en relación al cáncer-Mayo 2018. Montevideo: CHLCC, 2018. Disponible en: http://www.comisioncancer.org.uy/uc_513_1.html. Consulta: 27 enero 2019.
(2) Fondo Nacional de Recursos. Normativa de cobertura tomografía por emisión de positrones (PET SCAN). Montevideo: FNR, 2017. Disponible en: http://www.fnr.gub.uy/sites/default/files/normativas/tecnicas/n_pet_scan.pdf. Consulta: 14 febrero 2019.
(3) Bockisch A, Freudenberg L, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009; 39:276-89.
(4) Oldan JD, Shah SN, Rose TL. Applications of PET/MR imaging in urogynecologic and genitourinary cancers. Magn Reson Imaging Clin N Am 2017; 25:333-50.
(5) Barwick T, Rockall A. PET/CT in gynecological cancers. Clinicians’ guides to radionuclide hybrid imaging-PET/CT. Switzerland: Springer, 2016.
(6) Rao YJ, Grigsby PW. The role of PET imaging in gynecologic radiation oncology. PET Clin 2018; 13(2):225-37.
(7) Ohliger M, Hope T, Chapman J, Chen L, Behr S, Poder L. PET/MR imaging in gynecologic oncology. Magn Reson Imaging Clin N Am 2017; 25(3):667-84.
(8) Meads C, Davenport C, Malysiak S, Kowalska M, Zapalska A, Guest P. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121(4):398-407.
(9) Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects-a clinician’s perspective. Pet Clin 2010; 5(4):391-405.
(10) Paredes P, del Pino M, Vidal L. Presente y futuro de la tomografía por emisión de positrones y tomografía por emisión de positrones-tomografía computarizada en el manejo del cáncer ginecológico. Prog Obstet Ginecol 2015; 58(3):150- 62.
(11) Goyal BK, Singh H, Kapur K, Duggal BS, Mattakarottu MJ. Value of PET-CT in avoiding multimodality therapy in operable cervical cancer. Int J Gynecol Cancer 2010; 20(6):1041-5.
(12) Lai CH, Yen TC, Ng KK. Molecular imaging in the management of cervical cancer. J Formos Med Assoc 2012; 111(8):412-20.
(13) Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, Cózar-Santiago M del P. Positron emission tomography in breast cancer. Diagnostics (Basel) 2015; 5(1):61-83.
(14) Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006; 98(3):267-74.
(15) Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49(3):480-508.
(16) Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O. Role of 2-18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1:156-61.
(17) Zucchini G, Quercia S, Zamagni C, Santini D, Taffurelli M, Fanti S, et al. Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer 2013; 49:1539-45.
(18) Antonsen S, Jensen L, Loft A. MRI, Berthelsen AK, Costa J, Tabor A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer-a multicenter prospective comparative study. Gynecol Oncol 2013; 128(2):300-8.
(19) Sierralta P, Jofré J, Massardo T, Canessa J, González P, Valdebenito R. Utilidad del PET-FDG en patología gineco-oncológica. Rev chil obstet ginecol 2007; 72(1):57-64.
(20) Lai CH, Lin G, Yen TC, Liu FY. Molecular imaging in the management of gynecologic malignancies. Gynecol Oncol 2014; 135(1):156-62.
(21) Marzola M, Chondrogiannis S, Rubello D. Fludeoxyglucose F 18 PET/CT assessment of ovarian cancer. PET Clin 2018; 13(2):179-202.
(22) Chou HH, Chen CY, Liu FY, Ling G, Wang CC, Yang LY, et al. Positron emission tomography in the management of documented or suspected recurrent ovarian cancer. J Formos Med Assoc 2017; 116(11):869-79.
(23) hen YM, Chen T, Zee CS, Shi YP, Wan LR, Tong LJ. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun 2014; 35(4):347-52.
(24) Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008; 108(1):160-5.
(25) Han EJ, Park HL, Lee YS, Park EK, Song MJ, Yoo IR, et al. Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy. Ann Nucl Med 2016; 30(9):600-7. DOI: 10.1007/s12149-016-1100-0.
(26) Peiróa V, Chiva L, González A, Bratos R, Alonso S, Márquez R, et al. Utilidad de la PET/TC en el manejo del cáncer de vulva. Rev Esp Med Nucl Imagen Mol 2014; 33(2):87-92.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
